Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Boehringer Ingelheim Pharmaceuticals, Inc.
EIR
•Boehringer Ingelheim Pharmaceuticals, Inc.•September 1, 2010

Boehringer Ingelheim Pharmaceuticals, Inc. – FDA EIR, Sep 1, 2010

Record Details

An FDA inspection of Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) in Danbury, CT, was conducted from August 23 to September 1, 2010. This joint FDA/European Medicines Agency inspection focused on BIPI's sponsor and monitor responsibilities for a specific clinical trial supporting a new drug submission. The inspection identified three significant observations, documented on a Form FDA 483. First, BIPI failed to formally document the transfer of obligations to three contract research organizations in writing before the clinical trial commenced, violating 21 CFR 312.52(a). Second, there was a failure to ensure proper study monitoring, as an approved Trial Monitoring Manual was not provided to monitoring staff prior to trial initiation, and instances of undocumented monitoring visits at a clinical site were noted. Furthermore, an approved Event Adjudication Committee Charter was not established before case reviews began, which is a breach of 21 CFR 312.50. Third, the company did not ensure foreign clinical research complied with ethical principles and local regulations (21 CFR 312.120(c)). Specifically, vital status information was collected from subjects who withdrew consent at foreign sites without documented Ethics Committee approval. BIPI acknowledged these observations at the exit discussion and committed to providing written responses, which were subsequently submitted on September 14 and 16, 2010, detailing corrective actions.

Company
Boehringer Ingelheim Pharmaceuticals, Inc.
Inspection date
September 1, 2010
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • Michelle M. Noe (investigator)
  • M. Patricia Murphy (investigator)
  • Sharon K. Gershon (investigator)
  • Christopher D. Corsico (recipient)
  • Jeanne Varrone (company_representative)
View Company Profile

ID · c2f00c08-0e01-4f3f-bbfa-5466b71914d6

Violation Codes3
21 CFR 312.5021 CFR 312.52(a)21 CFR 312.120(c)

Full citation text and observation details available on the Dashboard.

Other documents for Boehringer Ingelheim Pharmaceuticals, Inc.
  • 483 - 2025-09-11September 11, 2025
  • 483 - 2019-12-12December 12, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Boehringer Ingelheim Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.